MASTERMIND is an opportunity for informal CEO peer-to-peer conversations. Each MASTERMIND is anchored by a member willing to share and discuss a particular experience / expertise. These sessions are confidential and not recorded.

Bill Enright is the CEO of Vaccitech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic and vaccines for the treatment and prevention of infectious diseases, cancer & autoimmune diseases. Vaccitech began trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol “VACC.”

The company’s proprietary platforms comprise proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans, and the SNAPvax™ and Syntholytic™ polymer-based platforms. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs.

Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.